BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that it
will release its financial results for the quarter and year ended
December 31, 2013 on Monday, March 17, 2014, before the U.S. markets
open.
The Company will host a conference call on Monday, March 17 at 10:00
a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., CEO of
BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of
BioLineRx. A presentation will be provided on BioLineRx’s website, to
accompany management’s remarks on the conference call. The conference
call will be available via webcast and can be accessed through the
Investor Relations section of BioLineRx’s website, www.biolinerx.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-668-9141 from the U.S. or
+972-3-918-0609 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at
www.biolinerx.com. A dial-in replay of the call will be available
until March 20, 2014; please dial 1-888-269-0005 from the U.S. or
+972-3-925-5938 internationally.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid
leukemia (AML) and other hematological indications, which is in the
midst of a Phase 2 study; BL-7010 for celiac disease, which is in the
midst of a Phase 1/2 study; and BL-5010 for non-surgical removal of skin
lesions, which is expected to commence a pivotal CE-mark registration
trial in the first half of 2014.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the “Risk Factors” section
of BioLineRx’s most recent annual report on Form 20-F filed with the
Securities and Exchange Commission on March 12, 2013. In addition, any
forward-looking statements represent BioLineRx’s views only as of the
date of this release and should not be relied upon as representing its
views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by
law.
Copyright Business Wire 2014